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Abstract
Targeted expression of foreign genes to the peripheral nervous system is interesting for many
applications, including gene therapy of neuromuscular diseases, neuroanatomical studies, and
elucidation of mechanisms of axonal flow. Here we describe a microneurosurgical technique for
injection of replication-defective viral vectors into dorsal root ganglia (DRG). Adenovirus- and
adeno-associated virus-based vectors with transcriptional competence for DRG neurons led to
expression of the gene of interest throughout the first neuron of the sensory system, from the distal
portions of the respective sensory nerve to the ipsilateral nucleus gracilis and cuneatus, which contains
the synapses to the spinothalamic tracts. Use of Rag-1 ablated mice, which lack all B and T
lymphocytes, allowed for sustained expression for periods exceeding 100 days. In immunocompetent
mice, long-term (52 days) expression was achieved with similar efficiency by using adeno-associated
viral vectors. DRG injection was vastly superior to intraneural injection into the sciatic nerve, which
mainly transduced Schwann cells in the vicinity of the site of inoculation site but only inefficiently
transduced nerve fibers, whereas i.m. injection did not lead to any significant expression of the reporter
gene in nerve fibers. The versatile and efficient transduction of genes of interest should enable a wide
variety of functional studies of peripheral nervous system pathophysiology.
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Targeted expression of foreign genes to the peripheral nervous
system is interesting for many applications, including gene therapy
of neuromuscular diseases, neuroanatomical studies, and elucida-
tion of mechanisms of axonal flow. Here we describe a microneu-
rosurgical technique for injection of replication-defective viral
vectors into dorsal root ganglia (DRG). Adenovirus- and adeno-
associated virus-based vectors with transcriptional competence for
DRG neurons led to expression of the gene of interest throughout
the first neuron of the sensory system, from the distal portions of
the respective sensory nerve to the ipsilateral nucleus gracilis and
cuneatus, which contains the synapses to the spinothalamic tracts.
Use of Rag-1 ablated mice, which lack all B and T lymphocytes,
allowed for sustained expression for periods exceeding 100 days.
In immunocompetent mice, long-term (52 days) expression was
achieved with similar efficiency by using adeno-associated viral
vectors. DRG injection was vastly superior to intraneural injection
into the sciatic nerve, which mainly transduced Schwann cells in
the vicinity of the site of inoculation site but only inefficiently
transduced nerve fibers, whereas i.m. injection did not lead to any
significant expression of the reporter gene in nerve fibers. The
versatile and efficient transduction of genes of interest should
enable a wide variety of functional studies of peripheral nervous
system pathophysiology.
dorsal root ganglia u gene therapy
Successful gene transfer depends on efficient methods ofexpressing genes of interest into appropriate cell popula-
tions. A particularly efficient and safe way of delivering genes to
postmitotic cells uses adenoviral vectors and vectors based on
recombinant adeno-associated viruses (rAAVs) (1–3).
Gene transfer to the peripheral nervous system (PNS) poses
an exceptional challenge because the PNS contains a wide range
of cell types, many of which are postmitotic. Delivery of genes
selectively to the PNS could have several important applications
for gene therapy of neurological diseases. In addition to ana-
tomical studies, direct viral vector-mediated gene transfer allows
for exact studies of physiological processes like antero- and
retrograde transport and sorting of viruses andyor proteins
along axons and dendrites (4–7). Delivery of genes encoding
proteins such as neurotrophic factors selectively to the PNS may
provide novel therapeutic approaches for spinal muscular atro-
phy, amyotrophic lateral sclerosis, or hereditary motor sensory
neuropathies (8, 9).
The effectiveness of gene therapy using viral vectors depends
among other factors on the efficient delivery of the desired genes
to the cell population of interest. In past investigations, delivery
was mainly accomplished by i.m. injection, which is followed by
uptake and retrograde axonal transport of virions (6, 9). In the
present study we have reasoned that direct transfer to PNS
neurons might be more efficient than methods relying on indirect
transduction to neurons. We found direct injection of dorsal root
ganglia (DRG) to be the most efficient technique.
Materials and Methods
Adenoviral Vectors. E1yE3-deleted adenoviral vectors, AdCMV-
lacZ and AdRSVlacZ, were generated by homologous recom-
bination in E1-transcomplementing 911 cells (10) between a
plasmid containing the expression cassette, 5.5 kb of viral DNA,
and a ClaI-restricted DNA fragment isolated from AdMLPlacZ.
Viral plaques were screened for expression of b-galactosidase
(b-gal) by PCR and amplified in 911 cells. Batches were purified
by CsCl gradient centrifugation, dialyzed against storage buffer
(10% glycerol in PBS at pH 7.2), and kept at 280°C. Viral titers
were determined by plaque assay and expressed as plaque-
forming units. Transfer plasmids, pAdCMVlacZ and pAdRSV-
lacZ, contained b-gal linked to the cytomegalovirus (CMV)
promoter (11) or the Rous sarcoma virus (RSV) enhanc-
erypromoter (pRcRSV, Invitrogen). To replace the CMV pro-
moter, pAdRSVlacZ was generated in a three-way ligation. The
SpeI–SalI 13-kb backbone of pAdCMVlacZ was joined to two
fragments generated by PCR with Pfu polymerase (Stratagene),
the SpeI–SfiI 450-bp product containing the Ad-inverted termi-
nal repeats was prepared by using pAdCMVlacZ as template and
primer P109 (59-GCTCTAGAACTAGTTGATC) and P110 (59-
GCAGATTCTTCATGCAATGGCCAGCTTGGCCATAAT-
AATAAAACGCCAAC). The SfiI–SalI 500-bp product con-
taining the RSV promoter was prepared by using pRcyRSV as
template and primer P111 (59-CGTTACTAGTGGAGTCGA-
CCTCGGATCCAAGCTTGGAGG) and P112 (59-ATTATG-
GCCAAGCTGGCCATTGCATGAAGAATCTGC).
Adeno-Associated Viral Vectors. PsubCMV-b was obtained by
inserting the EcoRIyHindIII CMV-lacZ-poly(A) expression
cassette from pCMV-b (CLONTECH) in XbaI sites of psub201
(12). To produce psubCMV-WPRE, lacZ was replaced by a
multiple cloning site into which the 0.59-kb ClaIyClaIWPRE
fragment from p138WPRE was cloned (13). The CMV promoter
was replaced by a 1.48-kb XbalySalI fragment from the human
platelet-derived growth factor (PDGF) b-chain promoter to
generate psub-PDGF-WPRE. The rAAV vector plasmid psub-
PDGF-WPRE-EGFP was obtained by cloning the NheI–NotI
enhanced green fluorescent protein (EGFP) fragment from
pEGFP-N1 (CLONTECH) between the PDGF promoter and
the WPRE element of psub-PDGF-WPRE. For generation of
the adeno helper plasmid pBS-E2A-VA-E4, the 1.38-kb
SalIyApaI VA fragment, the 5.77-kb BamHIyEcoRI E2A frag-
ment and the 4.0-kb Apal 39 terminal E4 fragment from adeno-
virus type 5 genomic DNA were cloned in pBluescript SK1
Abbreviations: PNS, peripheral nervous system; DRG, dorsal root ganglia; rAAV, recombi-
nant adeno-associated virus; b-gal, b-galactosidase; CMV, cytomegalovirus; RSV, Rous
sarcoma virus; PDGF, platelet-derived growth factor; EGFP, enhanced green fluorescent
protein.
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(Stratagene). The rAAV packaging plasmid pAAVyAd-
rep(ACG) was generated by PCR mutagenesis of the Rep78 start
codon from ATG to ACG in the pAAVyAd plasmid (12).
rAAV-PDGF-EGFP virus particles were produced in an
adenovirus-free system (14) by cotransfection of 293T cells with
psubPDGF-WPRE-EGFP, the rAAV packaging plasmid
pAAVyAd-rep(ACG), which contains the rep and cap genes and
the adenovirus helper plasmid pBS-E2A-VA-E4, by using the
calcium phosphate method. Cells were collected and lysed by
three freeze-thaw cycles, and debris was eliminated by centrif-
ugation. Some contaminant proteins were removed by precipi-
tation with 25% ammonium sulfate. rAAV-PDGF-EGFP was
further purified over two consecutive CsCl gradients, dialyzed
against PBS containing 1 mM MgCl2, and stored at 280°C in the
presence of 10% glycerol. Viral particle numbers, as determined
by slot blot hybridization, were 1.5 3 1010yml.
Procedures for Viral Administration to Animals. For all experiments
with rAAV vectors we used C57BLy6 mice, whereas all exper-
iments with replication-deficient adenovirus were performed
with Rag-12/2 mice (15). Three microliters of PBS or storage
buffer containing 2.5 3 107 plaque-forming units of AdCMV-
lacZ was injected into the musculus tibialis cranialis over 5 min.
One mouse of the adenovirally transduced group received
additionally 3 ml PBS into the contralateral musculus tibialis
cranialis. For intranerval injection, mice were anaesthetized with
Fig. 1. Expression of b-gal activity in DRG (A, C, E, and G) and sciatic nerves (B, D, F, and H) after injection of AdCMVlacZ in the sciatic nerve (A and B), AdCMVlacZ
in the DRG (C and D), AdRSVlacZ in the DRG (E and F), and PBS in the DRG (G and H). Sections were stained with bluo-gal and counterstained with nuclear fast
red. The blue color visualizes cells expressing b-gal. (A and B) 102 days after injection (A, 365; B, 3100). (C and D) 14 days after injection (C, 365; D, 3100). (E
and F) 24 days after injection (E, 365; F, 3100). (G and H) Control animal, 14 days after injection (G, 365; H, 3100). (A and B) expression of b-gal in Schwann cells
(block arrow), cells of the epineurium, and axons. There is no significant expression of b-gal in the DRG. (C–F) DRG neurons and axons (arrow) express b-gal.
Expression of b-gal is detectable to a lesser extent in Schwann cells and cells of the epineurium. dr, dorsal root; drg, dorsal root ganglia.
Table 1. Summary of the results from the i.m., intranerval, and DRG injections




analysis, days Cell types transduced
Muscle AdCMVlacZ 3 2 7–21 – 2
Sciatic nerve AdRSVlacZ 4 11 2–21 Epineurium 11
Schwann cells 111
Neurons 1
AdCMVlacZ 6 11 2–102 Epineurium 11
Schwann cells 111
Neurons 1
DRG AdRSVlacZ 4 111 2–24 Epineurium 1
Schwann cells 1
Neurons 111
AdCMVlacZ 6 111 2–50 Epineurium 1
Schwann cells 1
Neurons 111
rPDGF-AAV-EGFP 6 111 16–52 Epineurium 2
Schwann cells 2
Neurons 111









xylazinyketamin, and the right sciatic nerve was surgically
exposed by dislodging the musculus gluteus superficialis and the
musculus biceps femoris. The nerve was gently placed onto a
metal plate (20 3 5 3 0.5 mm), and 2.5 3 107 plaque-forming
units of AdCMVlacZ or of AdRSVlacZ (3 ml) were injected with
a 34-gauge Hamilton syringe over 5 min (16). The nerve was
anatomically repositioned, and the skin was closed with USP 4.0
nylon sutures. Two mice of the adenovirally transduced group
received additionally 3 ml of PBS in the contralateral sciatic
nerve. One additional control mouse received 3 ml of PBS in the
right sciatic nerve.
For DRG injection, mice were anaesthetized with xyla-
zinyketamin. DRG (levels L4yL5) were surgically exposed by
dissecting the musculus multifidus and the musculus longissimus
lumborum and by removing the processus accessorius and parts
of the processus transversus. AdCMVlacZ or AdRSVlacZ (2.5 3
107 plaque-forming units) or 6 3 107 particles of rAAV-PDGF-
EGFP suspended in 4 ml (2 ml per ganglion) were injected. Two
mice of the adenovirally transduced group received additionally
4 ml of PBS in the contralateral L4yL5 DRG. One (adenoviral
group) or three (rAAV group) control mice received 4 ml of PBS
in the right L4yL5 DRG. All injections were done by using a
stereotaxic frame and a Hamilton syringe with a 34-gauge needle
over 5 min. Muscles then were adapted by using USP 5.0 catgut.
Skin closure was achieved with 4.0 nylon suture.
Morphological and DNA Analysis. All mice were anaesthetized with
xylazinyketamin and perfused with PBS containing 2% para-
formaldehyde and 0.5% glutaraldehyde at defined time points.
For b-gal analysis, brains, spinal cords, and both sciatic nerves
were removed and postfixed in the same solution (4 h). Tissue
was rinsed with PBS, reacted in 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, 2 mM MgCl2, 0,01% (wtyvol) sodium deoxycholate,
0,02% NP-40, and 1 mgyml Bluo-gal (Sigma) in PBS for 4–6 h.
For EGFP detection, mice were perfused with the same fixative
as above, and sciatic nerves and spinal cord were processed for
whole mounts and cryosectioning. Samples were embedded in
paraffin, cut in 4-mm sections, and counterstained with nuclear
fast red or Sudan black. Selected slides were double-stained for
neurofilaments (mAb against neurofilament protein 70 kDa and
200 kDa, 1:20, Bio-Science, Emmenbru¨cke, Switzerland). Visu-
alization was achieved with biotinylated secondary antibody
(Dako, 1:20), biotinyavidin-peroxidase (Dako), and diamino-
benzidine.
After postfixation with 0.5% glutaraldehyde, selected samples
were fixed with osmic tetroxide and embedded in epoxy resin.
Sections (3 mm) were stained with toluidine blue. Expression of
EGFP was detected by fluorescence and confocal laser scanning
microscopy on whole-mount preparations of the sciatic nerve.
Whole-mount sections were double or separately stained for
neurofilament and EGFP. For detection of EGFP, a mAb
(Chemicon, 1:500) was used, and neurofilaments were detected
with a polyclonal rabbit anti-mouse antibody (Chemicon, 1:200).
Visualization was achieved by using alexa 546-labeled goat
anti-mouse (Molecular Probes, 1:2,000) or FITC-labeled goat
anti-rabbit antibody (Sigma, 1:750).
For PCR, DNA was extracted from DRG and midsciatic
nerves of mice upon microdissection of frozen sections. Two
primers (59-CAGTGGCCAATGGTGAGCAAGGGCGAGG-
AGC-39 and 59-TGTAGGTACCCTCTGCCATGCCGAGAG-
TGATCC-39) were used to amplify the entire ORF of EGFP.
Results
No b-Gal Activity in the PNS After i.m. Injection of Adenoviral Vectors
Containing the lacZ Gene into the Musculus Tibialis Cranialis.
AdCMVlacZ was injected i.m. in three mice. Another mouse
received PBS. For detection of b-gal activity, sciatic nerves and
spinal cords were examined as whole mounts under a dissection
microscope. In addition, histological sections from the sciatic
nerve or the spinal cord were examined at various magnifica-
tions. However, in contrast to previous reports, no b-gal activity
was detectable in any of the examined samples at any time point
(9) (7, 14, or 21 days) (Table 1).
Localized b-Gal Activity After Intranerval Injection in the Sciatic Nerve
of Adenoviral Vectors Containing the lacZ Gene. Of 10 mice injected
into the sciatic nerve, eight showed expression of b-gal predom-
inantly confined to the immediate neighborhood of the site of
injection. Histologically, expression was seen mainly in Schwann
cells and perineural tissue. Axonal expression also was seen, but
to a much lesser extent (Figs. 1 and 2). The amount and
distribution of b-gal activity was identical in animals that had
received the adenoviral vector encoding CMV-lacZ and those
injected with the RSV-lacZ vector. In the contralateral nonin-
jected side and in mice receiving PBS there was no detectable
b-gal activity.
At 2 days and 1 week, b-gal activity was prominent mainly in
Schwann cells in the area of the injection site. At later time points
Fig. 2. Immunohistochemistry for neurofilament protein (A and C) and
Sudan black stain (B and D) of sciatic nerves 50 days after injection of AdCM-
VlacZ in the DRG L4yL5 (A and B) or the sciatic nerve (C and D). b-gal expression
and immunopositivity for neurofilament proteins colocalize in A. (E and F)
Semithin sections of the plexus lumbalis: no significant demyelination is
visible. Occasional axonal degeneration is marked with an arrow. (F) After
AdCMVlacZ injection in the DRG. (E) Healthy nonmanipulated mouse. ax,
axon; ms, myelin sheath; NFP, neurofilament immunohistochemistry; SB, su-
dan black stain. Magnifications: 3260.
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(2 and 3 weeks) activity was detected in the distal sciatic nerve
and the plexus lumbalis including the DRG up to 30 mm from
the injection site (Figs. 3 and 4). Two of four mice displayed
expression of b-gal in the fasciculus gracilis at later time points
(2 and 3 weeks). Expression was stable and strong in all mice
taken at later time points. One mouse taken at 102 days still
showed a strong expression of b-gal (Fig. 1B).
Stable and Widespread b-Gal Activity in the Sensory Pathway After
Injection of Adenoviral Vectors Containing the lacZ Gene in the DRG
L4yL5. Of 10 mice injected in the DRG, all showed strong
expression of b-gal activity. On histological sections, expression
was seen predominantly in neurons, whereas satellite cells and
perineural tissue showed lower levels of b-gal activity (Figs. 1
and 2). Ganglion cells in the injected DRG showed strong
expression of b-gal in their cytosol (Fig. 1). The use of a CMV
promoter provided no significant advantages over the RSV
promoter in the DRG injections. In two mice receiving PBS in
contralateral DRG and in two mice receiving PBS only in the
right DRG no b-gal activity could be detected.
Even at early time points (5 days and 1 week) b-gal activity was
strong both in the vicinity of the injection sites and in areas
situated up to 12 mm from the injection site (Figs. 1 and 3). At
later time points (2 weeks and 24 days) b-gal activity could be
seen in all mice in areas very distant from the injection site, such
as the distal parts of the sciatic nerve and the cranial third of the
fasciculus gracilis in the spinal cord (Figs. 3 and 4). In AdCM-
VlacZ-injected mice, 2 weeks after injection b-gal activity was
detected in the posterior thoracic portion of the spinal cord.
Three weeks after injection b-gal activity was detected in the
cervical portion of the spinal cord and in the medulla oblongata.
In AdRSVlacZ-injected mice, b-gal activity was detected in the
thoracic portion of the spinal cord at 24 days and in the cervical
spinal cord and medulla oblongata at 34 days (Figs. 3 and 4).
Expression was stable and strong in all mice up to 50 days.
Stable and Widespread Expression of EGFP in the Sensory Pathway
After Injection of rAAV Containing the EGFP Gene in the DRG L4yL5.
Of six mice that received rAAV-PDGF-EGFP in the DRG, four
showed expression of EGFP in the PNS. Confocal f luorescent
Fig. 3. Expression of b-gal in sciatic nerve and spinal cord of mice after stereotaxic administration of AdRSVlacZ into DRG (segments L4 and L5). (A and B) Five
days after injection of AdRSVlacZ: Expression of b-gal extends to the middle part of the sciatic nerve and is visible in the dorsal root of the spinal cord. (C)
Twenty-four days after injection of AdRSVlacZ, b-gal expression is prominent throughout the sciatic nerve. (D and E) Cross-section of the thoracic spinal cord (D)
and dorsal view of the spinal cord and the medulla oblongata (E) 34 days after injection of AdRSVlacZ. Strong b-gal expression is now seen in the thoracic fasciculus
gracilis (fg) and to a lesser extent in the medulla oblongata. Arrows in E mark the fasciulus gracilis: left arrow, caudal part of the fg; right arrow, cranial part
of the fg. sc, sciatic nerve; drg, dorsal root ganglia.
Fig. 4. Expression of b-gal activity in the brain, spinal cord, and sciatic nerves
7 days after administration of AdCMVlacZ (A), 34 days after injection of
AdRSVlacZ (B) into DRG of lumbar segments L4 and L5. Strong expression of
b-gal along the sciatic nerve (sc), in DRG (A and B), and in the fasciculus
gracilis (B).









analysis of rAAV-PDGF-EGFP-injected mice showed selective
expression of the gene in axons and cell bodies of DRG (Fig. 5).
Simultaneous immunofluorescent staining for neurofilaments,
(which are expressed in axons) and EGFP showed colocalization
of the EGFP and neurofilament expression (Fig. 5). Three
control mice receiving PBS did not show any EGFP-like fluo-
rescence. In the rAAV genomic context, the neuron-specific
PDGF promoter led to highly selective expression of EGFP in
DRG and their dendrites. In two mice taken at 16 days we could
not observe any expression of EGFP. In contrast, expression of
EGFP in mice taken at 45 days was strong, and no reduction of
expression was detectable at the latest time point of 52 days (Fig.
5). PCR analysis confirmed persistence of rAAV in DRG at 45
days; viral DNA was detectable in DRG but not in sciatic nerves
(Fig. 5F).
Neurotoxic Effects. The occurrence of possible neurotoxic effects
secondary to expression of transduced proteins, or to direct
neurotoxicity of the adenoviral structural proteins, was studied
by observing mice for signs of paresis and by scoring histologi-
cally sciatic nerves for the presence of demyelination, digestion
chambers, and axonal loss. One mouse was eliminated because
it showed paresis persisting at day 5 after injection. This mouse
is not included in Table 1. Of 23 mice injected with adenoviral
vectors, six showed transient paresis lasting 3–4 days. In the
group of mice that received i.m. injections no transient or
permanent pareses were observed. There was no difference in
incidence or severity of paresis between mice injected in the
sciatic nerve or DRG (data not shown). Histologically, there was
no apparent demyelination in mice injected in the sciatic nerve
nor in the DRG (Fig. 2). However in one DRG-injected mouse
minimal Wallerian degeneration was visible in semithin sections
50 days after viral administration (Fig. 2F).
All of the rAAV-injected mice fully recovered within 2 days
of the operation. With the exception of transient paresis ob-
served in two of six mice there were no clinical signs of
neurotoxic effects. Selected mice were histologically scored for
the presence of demyelination or digestion chambers: We could
not observe neurotoxic effects in any of these mice.
Discussion
Adenoviral and rAAV-based vectors are routinely used for
transferring genes to postmitotic cells (17–20). Transfer of genes
to the PNS was described by injection of the adenovirus into the
sciatic nerve or muscles (2, 9). However administration of
adenoviral vectors by intranerval injection leads to predominant
expression in the injected area, which typically exceeds the
expression levels achieved along the actual neural pathway.
According to published studies, this problem may be obviated by
i.m. injection of the virus (8, 9), yet in our study i.m. injection did
not lead to any detectable expression of the reporter gene in
either the PNS or the spinal cord. In our hands, injection into the
sciatic nerve led to b-gal activity in the vicinity of the injection
site and to a much lesser extent in regions distant from the
injection site. Moreover the cell populations successfully trans-
duced consisted predominantly of Schwann cells and mesenchy-
mal cells in the perineurium (21).
Here we introduce a strategy for delivering genes to the PNS,
which leads to specific and strong expression along sensory
neural pathways. By injecting viral vectors directly into the DRG
we achieved strong expression of the gene in remote segments of
the corresponding neuronal processes, such as the distal sciatic
nerve and the entire length of the fasciculus gracilis. Therefore,
Fig. 5. Expression of EGFP in the sciatic nerves and the DRG 45 days (A and B) and 52 days after injection of rAAV-PDGF-EGFP in the DRG L4yL5 (C–E). (A) Strong
expression of EGFP in some DRG neurons (L4). (B) In the middle region of the sciatic nerve, axons express EGFP. (C) Alexa 546-labeled EGFP expression in the middle
sciatic nerve. (D and E) Colocalization of Alexa 546-labeled EGFP (D) and FITC-labeled neurofilament (E) expression. (F) PCR analysis of DRG and mid-sciatic nerves
(scn) in rAAV-PDGF-EGFP-injected (gfp) and PBS-injected (pbs) animals 45 days after injection. A 700-bp GFP fragment can be amplified from DRG, but not from
scn, of AAV-injected animals. 1, 25 pg of PDGF-EGFP plasmid. (A and B) Confocal laser scanning microscopy, 325. (B–E) Conventional fluorescence microscopy,
3100. Arrows, axons; arrowhead, DRG.
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this strategy allows for expression of the gene of interest along
the entire length of a sensory dorsal root neuron, the longest
neural pathway in vertebrates. Neurons were predominantly
transduced, whereas Schwann and perineurial cells were trans-
duced to a lesser extent.
To assess the impact of different transcriptional regulatory
elements on the efficiency of transduction and gene expression,
we evaluated adenoviral vectors in which the gene of interest was
driven by the CMV immediate early promoter or the RSV
enhancerypromoter: both promoters have been shown to trans-
duce cells of the nervous system (17, 18). The use of the CMV
promoter was particularly attractive because CMV has been
implicated as a causative agent of dorsal root ganglionitis (22),
suggesting a strong tropism for DRG neurons. However, we did
not find any differences in efficiency of cell transduction or
duration of gene expression between the CMV and RSV pro-
moters. The neuron-specific PDGF promoter within an rAAV
vector led to highly selective and long-lasting transduction of
ganglion cells. For transduction of central nervous system neu-
rons the PDGF promoter within the context of the rAAV vector
had been shown to be superior to other tested promoters (23).
We were concerned about possible neurotoxic effects induced
by viral or transgenic expression (24). However, there was no
significant difference in the incidence of neurological side effects
between the groups of mice administered intranervally and those
injected into the DRG despite the much higher efficiency of the
latter procedure. Fibers with very high expression of b-gal
showed signs of axonal degeneration with occasional digestion
chambers resembling Wallerian degeneration. In contrast, neu-
rotoxic effects were absent from mice injected with rAAV apart
from transient paresis, in accordance with the lack of central
nervous system neurotoxicity of rAAV (3).
Although adenoviral vectors represent a promising tool for
transferring foreign genes to many tissue compartments, expres-
sion of transduced genes in immunocompetent animals is typi-
cally transient. We therefore used Rag-12/2 mice that lack all
differentiated B and T cells. In these mice we achieved stable,
strong expression for up to 102 days. Because there was no
decline in expression we conclude that expression is likely to last
for periods of time well exceeding our last time point. The above
findings confirm and add to the large body of evidence pointing
to the rate-limiting role of the immune response to genes
expressed by adenoviral vectors on the duration of expression
(15, 19, 24–27). We have not attempted to systematically inves-
tigate duration of expression in immunocompetent mice; how-
ever, in many experimental models the use of immunodeficient
animals may be acceptable.
To overcome the problem of immune response we used an
rAAV vector in immunocompetent mice. Histological analysis
did not reveal any inflammatory response to the viral vector or
EGFP. The delayed expression of the gene of interest is most
likely caused by the conversion of the AAV single-stranded
DNA to double-stranded DNA, which was shown to be the
rate-limiting step for efficient expression (28).
The methods detailed in the present study will allow investi-
gations of neuroregeneration and studies on the neurotropism of
infectious agents. For instance, we are using the system described
here to express the prion protein in the peripheral nervous
system of prion protein knockout mice (29) to study the role of
normal cellular prion protein in the spread of infectious prions
from peripheral sites to the central nervous system (30). In
addition, the strong expression in neural processes renders this
system particularly attractive for neuroanatomical tracing studies
(31).
As an ultimate goal, delivery of genes specifically to the PNS
of humans could be useful in treating diseases affecting the PNS,
such as toxic or metabolic axonal neuropathies. With this goal in
mind, the delivery of genes via injection into DRG seems to be
an efficient addition to the collection of tools for gene therapy.
We thank Dr. P. Gambetti for suggestions, Dr. M. Perricaudet for
providing the parental adenoviral vector ADMLPlacZ, Dr. T. Ba¨chi for
assistance with confocal microscopy, and M. Ko¨nig and M. Peltola for
technical help. This study was supported by grants of the Swiss Nation-
alfonds (NFP38y381), the European Union (98.6040, 98.6015), and the
National Institutes of Health (5P01 AG-1435902) to A.A., and a long-
term EMBO fellowship to B.N.
1. Federoff, H. J., Brooks, A., Muhkerjee, B. & Corden, T. (1997) J. Neurosci.
Methods 71, 133–142.
2. Hermens, W. T., Giger, R. J., Holtmaat, A. J., Dijkhuizen, P. A., Houweling,
D. A. & Verhaagen, J. (1997) J. Neurosci. Methods 71, 85–98.
3. Xiao, X., Li, J., McCown, T. J. & Samulski, R. J. (1997) Exp. Neurol. 144,
113–124.
4. Baumgartner, B. J. & Shine, H. D. (1998) Exp. Neurol. 153, 102–112.
5. Ghadge, G. D., Roos, R. P., Kang, U. J., Wollmann, R., Fishman, P. S.,
Kalynych, A. M., Barr, E. & Leiden, J. M. (1995) Gene Ther. 2, 132–137.
6. Kuo, H., Ingram, D. K., Crystal, R. G., Mastrangeli, A., Ghadge, G. D., Roos,
R. P., Kang, U. J., Wollmann, R., Fishman, P. S., Kalynych, A. M., et al. (1995)
Brain Res. 705, 31–38.
7. Terada, S., Nakata, T., Peterson, A. C. & Hirokawa, N. (1996) Science 273,
784–788.
8. Haase, G., Kennel, P., Pettmann, B., Vigne, E., Akli, S., Revah, F., Schmal-
bruch, H. & Kahn, A. (1997) Nat. Med. 3, 429–436.
9. Haase, G., Pettmann, B., Vigne, E., Castelnau-Ptakhine, L., Schmalbruch, H.
& Kahn, A. (1998) J. Neurol. Sci. 160, Suppl. 1, 97–105.
10. Fallaux, F. J., Kranenburg, O., Cramer, S. J., Houweling, A., Van Ormondt, H.,
Hoeben, R. C. & Van Der Eb, A. J. (1996) Hum. Gene Ther. 7, 215–222.
11. Schneider, S. D., Rusconi, S., Seger, R. A. & Hossle, J. P. (1997) Gene Ther.
4, 524–532.
12. Samulski, R. J., Chang, L. S. & Shenk, T. (1989) J. Virol. 63, 3822–3828.
13. Donello, J. E., Loeb, J. E. & Hope, T. J. (1998) J. Virol. 72, 5085–5092.
14. Xiao, X., Li, J. & Samulski, R. J. (1998) J. Virol. 72, 2224–2232.
15. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. &
Papaioannou, V. E. (1992) Cell 68, 869–877.
16. Bassant, M. H., Baron, H., Gumpel, M., Cathala, F. & Court, L. (1986) Brain
Res. 383, 397–401.
17. Akli, S., Caillaud, C., Vigne, E., Stratford Perricaudet, L. D., Poenaru, L.,
Perricaudet, M., Kahn, A. & Peschanski, M. R. (1993) Nat. Genet. 3, 224–228.
18. Bajocchi, G., Feldman, S. H., Crystal, R. G. & Mastrangeli, A. (1993) Nat.
Genet. 3, 229–234.
19. Benihoud, K., Saggio, I., Opolon, P., Salone, B., Amiot, F., Connault, E.,
Chianale, C., Dautry, F., Yeh, P. & Perricaudet, M. (1998) J. Virol. 72,
9514–9525.
20. McCown, T. J., Xiao, X., Li, J., Breese, G. R. & Samulski, R. J. (1996) Brain
Res. 713, 99–107.
21. Shy, M. E., Tani, M., Shi, Y. J., Whyatt, S. A., Chbihi, T., Scherer, S. S. &
Kamholz, J. (1995) Ann. Neurol. 38, 429–436.
22. Fuller, G. N., Jacobs, J. M. & Guiloff, R. J. (1989) Lancet 2, 937–941.
23. Peel, A. L., Zolotukhin, S., Schrimsher, G. W., Muzyczka, N. & Reier, P. J.
(1997) Gene Ther. 4, 16–24.
24. Kajiwara, K., Byrnes, A. P., Charlton, H. M., Wood, M. J. & Wood, K. J. (1997)
Hum. Gene Ther. 8, 253–265.
25. Smith, T. A., White, B. D., Gardner, J. M., Kaleko, M. & McClelland, A. (1996)
Gene Ther. 3, 496–502.
26. Parr, M. J., Wen, P. Y., Schaub, M., Khoury, S. J., Sayegh, M. H. & Fine, H. A.
(1998) J. Neurovirol. 4, 194–203.
27. Zhang, H. G., Zhou, T., Yang, P., Edwards, C. K., Curiel, D. T. & Mountz, J. D.
(1998) Hum. Gene Ther. 9, 1875–1884.
28. Ferrari, F. K., Samulski, T., Shenk, T. & Samulski, R. J. (1996) J. Virol. 70,
3227–3234.
29. Bu¨eler, H. R., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., DeArmond,
S. J., Prusiner, S. B., Aguet, M. & Weissmann, C. (1992) Nature (London) 356,
577–582.
30. Bla¨ttler, T., Brandner, S., Raeber, A. J., Klein, M. A., Voigtla¨nder, T.,
Weissmann, C. & Aguzzi, A. (1997) Nature (London) 389, 69–73.
31. Kuo, H., Ingram, D. K., Crystal, R. G. & Mastrangeli, A. (1995) Brain Res. 705,
31–38.
Glatzel et al. PNAS u January 4, 2000 u vol. 97 u no. 1 u 447
N
EU
RO
BI
O
LO
G
Y
